Overcoming 5-FU Resistance in Gastric Cancer with LY294002
Author Information
Author(s): Shin Jung-Young, Kim Jeong-Oh, Lee Suk Kyeong, Chae Hiun-Suk, Kang Jin-Hyoung
Primary Institution: The Catholic University of Korea
Hypothesis
Can the combination of 5-FU and LY294002 overcome resistance in EBV-positive gastric cancer cells?
Conclusion
The sequential combination of 5-FU and LY294002 can induce synergistic cytotoxicity and overcome resistance in EBV-positive gastric cancer cells.
Supporting Evidence
- 5-FU and LY294002 together showed a synergistic effect in reducing cancer cell growth.
- Sequential treatment decreased the expression of p-AKT and p-NFκB, which are linked to drug resistance.
- Apoptosis was significantly increased in cells treated with the combination of 5-FU and LY294002.
Takeaway
This study found that using two cancer drugs together can help make cancer cells more sensitive to treatment, especially in a type of stomach cancer linked to a virus.
Methodology
The study used MTS assays, Western blot analysis, and flow cytometry to evaluate the effects of 5-FU and LY294002 on gastric cancer cells.
Limitations
The study primarily focused on in vitro results, which may not fully translate to in vivo conditions.
Participant Demographics
The study involved EBV-positive gastric cancer cell lines.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website